You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
PWNHealth will enable Stratify to offer its Prompt Personal Genetic Score prostate cancer genetic risk test directly to consumers with medical oversight.
A survey by University of Nebraska researchers found that both specialists and primary care healthcare providers largely interpreted genetic testing results correctly.
Researchers used single-cell sequencing to uncover developing brain cell populations from mice and humans with transcriptome features resembling those in pediatric brain tumors.
Using a single-nucleus RNA sequencing strategy, investigators tracked down cell type-specific gene expression and networks in Alzheimer's brains.
ONT called Illumina's revised remedies proposal an "illusory offer" that doesn't offset the anticompetitive effects of an Illumina-PacBio merger.
Asuragen will use its Amplidex PCR tech to develop companion diagnostics for Wave's investigational allele-selective therapeutic programs for Huntington's.
Last week, GenomeWeb's readers were most interested in the expansion of Illumina's offer to open sequencing-related IP held by Pacific Biosciences to competitors.
The company also said that it expects a clearance decision from US regulators in the near term on a lower respiratory tract infection test that runs on its Unyvero system.
Tokyo-based Eisai develops drugs primarily for the neurology and oncology markets, including treatments for Parkinson's disease and breast cancer.
News items for the week of Nov. 18, 2019.
A large genome-wide association in breast cancer cases and controls from Japan led to common variants linked to disease risk at two new and nine known risk loci.
The technology, called PrecisMed, is designed to detect, measure, and assess over 200 medications in a patient's bloodstream from a finger stick.
Under the terms of the five-year grant, Coriell will continue to support the NINDS Human Genetics Research Center.
Functional enhancers can accompany oncogenes on the circularized extrachromosomal amplicons found in glioma and other tumors, enhancing cancer growth.
LGC provides customers across multiple markets with reference materials, proficiency testing, oligonucleotides, genomics reagents, and instrumentation.
The company's antibiotic-induced hearing loss test will be used to screen babies for a genetic mutation that can cause deafness when given certain antibiotics.
Doctors can now order the test to identify breast cancer patients with BRCA1/2 mutations who may be eligible for surgery or targeted therapy.
The grant was awarded through the Alzheimer's Drug Discovery Foundation's Diagnostic Accelerator, a partnership between the charity and philanthropic partners.
In a revised remedies proposal to the UK's Competition and Markets Authority, Illumina offered licenses to a wider swath of IP held by it and PacBio.
Using RNA sequencing, researchers profiled gene expression patterns in cutaneous leishmaniasis lesions, identifying a handful of genes with treatment-associated expression.
The Redwood, California-based company plans to use the funding to drive the commercial launch of its semiconductor chip-based sequencing-by-synthesis instrument.
The flow cytometry-based assays were developed by Menlo Park, California-based IncellDx to run on Beckman Coulter instrumentation.
The T2Resistance Panel, which runs on the T2Dx instrument, detects 13 genes conferring antimicrobial resistance directly from whole blood in three to five hours.
Kelvin Droegemeier, the director of the White House Office of Science and Technology Policy, is the new acting director of the US National Science Foundation.
An opinion piece at the Guardian discusses the state of SARS-CoV-2 testing in the UK.
Wired reports the University of California, Berkeley's Innovative Genomics Institute has transformed itself into a diagnostic lab to run SARS-CoV-2 tests.
In Nature this week: direct-capture Perturb-seq approach for combinatorial single-cell CRISPR screens, potential uses of genome-editing in breeding crops, and more.